A previous breast cancer study from Bashkortostan identified c.5266dupC in some 4% of breast cancer patients [17], indicating a three– to fourfold enrichment of pathogenic BRCA1 variants in ovarian cancer compared to breast cancer from the same population. This evidence concerns the gene BRCA1 and breast carcinoma.